Patents by Inventor Krishnaswamy Srinivas Raghavan
Krishnaswamy Srinivas Raghavan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20150218179Abstract: A process for formulating certain epothilone analogs for parenteral administration is disclosed wherein the analog is dissolved in a mixture of at least 50% by volume tertiary-butanol in water, the mixture is lyophilized, the resulting lyophilized product is packaged in one vial with a sufficient amount of solvent comprising anhydrous ethanol and a suitable nonionic surfactant in a second vial. All steps are carried out with protection from light. In use, the contents of the second or diluent vial are added to the lyophilized product and mixed to constitute the epothilone analog and the resulting solution is diluted with a suitable diluent to produce a solution for intravenous injection containing the epothilone analog in a concentration of from about 0.1 mg/mL to about 0.9 mg/mL. A preferred surfactant is polyethoxylated castor oil and a preferred diluent is Lactated Ringer's Injection.Type: ApplicationFiled: April 14, 2015Publication date: August 6, 2015Inventors: Rebanta Bandyopadhyay, Timothy M. Malloy, Andrea Panaggio, Krishnaswamy Srinivas Raghavan, Sailesh Amilal Varia
-
Publication number: 20140107169Abstract: A process for formulating certain epothilone analogs for parenteral administration is disclosed wherein the analog is dissolved in a mixture of at least 50% by volume tertiary-butanol in water, the mixture is lyophilized, the resulting lyophilized product is packaged in one vial with a sufficient amount of solvent comprising anhydrous ethanol and a suitable nonionic surfactant in a second vial. All steps are carried out with protection from light. In use, the contents of the second or diluent vial are added to the lyophilized product and mixed to constitute the epothilone analog and the resulting solution is diluted with a suitable diluent to produce a solution for intravenous injection containing the epothilone analog in a concentration of from about 0.1 mg/mL to about 0.9 mg/mL. A preferred surfactant is polyethoxylated castor oil and a preferred diluent is Lactated Ringer's Injection.Type: ApplicationFiled: December 19, 2013Publication date: April 17, 2014Inventors: Rebanta Bandyopadhyay, Timothy M. Malloy, Andrea Panaggio, Krishnaswamy Srinivas Raghavan, Sailesh Amilal Varia
-
Patent number: 8632788Abstract: A process for formulating certain epothilone analogs for parenteral administration is disclosed wherein the analog is dissolved in a mixture of at least 50% by volume tertiary-butanol in water, the mixture is lyophilized, the resulting lyophilized product is packaged in one vial with a sufficient amount of solvent comprising anhydrous ethanol and a suitable nonionic surfactant in a second vial. All steps are carried out with protection from light. In use, the contents of the second or diluent vial are added to the lyophilized product and mixed to constitute the epothilone analog and the resulting solution is diluted with a suitable diluent to produce a solution for intravenous injection containing the epothilone analog in a concentration of from about 0.1 mg/mL to about 0.9 mg/mL. A preferred surfactant is polyethoxylated castor oil and a preferred diluent is Lactated Ringer's Injection.Type: GrantFiled: November 4, 2008Date of Patent: January 21, 2014Assignee: Bristol-Myers Squibb CompanyInventors: Rebanta Bandyopadhyay, Timothy M. Malloy, Andrea Panaggio, Krishnaswamy Srinivas Raghavan, Sailesh Amilal Varia
-
Patent number: 8252821Abstract: Pharmaceutical capsule compositions containing the active compound (2R)-2-[[(4-chlorophenyl)sulfonyl][[2-fluoro-4-(1,2,4-oxadiazol-3-yl)phenyl]methyl]amino]-5,5,5-trifluoropentanamide, and polyethylene glycol (PEG), Vitamin E polyethylene glycol succinate, polyvinylpryrrolidone (PVP) or copovidone (PVP-Polyvinyl acetate), with or without citric acid, are provided.Type: GrantFiled: April 12, 2010Date of Patent: August 28, 2012Assignee: Bristol-Myers Squibb CompanyInventors: Sachin Chandran, Rajesh Babulal Gandhi, Jaquan Kalani Levons, Robert Kevin Perrone, Christopher P. Price, Krishnaswamy Srinivas Raghavan, Ismat Ullah
-
Publication number: 20100260837Abstract: Pharmaceutical capsule compositions containing the active compound (2R)-2-[[(4-chlorophenyl)sulfonyl][[2-fluoro-4-(1,2,4-oxadiazol-3-yl)phenyl]methyl]amino]-5,5,5-trifluoropentanamide, and polyethylene glycol (PEG), Vitamin E polyethylene glycol succinate, polyvinylpryrrolidone (PVP) or copovidone (PVP-Polyvinyl acetate), with or without citric acid, are provided.Type: ApplicationFiled: April 12, 2010Publication date: October 14, 2010Inventors: Sachin Chandran, Rajesh Babulal Gandhi, Jaquan Kalani Levons, Robert Kevin Perrone, Christopher P. Price, Krishnaswamy Srinivas Raghavan, Ismat Ullah
-
Publication number: 20090069393Abstract: A process for formulating certain epothilone analogs for parenteral administration is disclosed wherein the analog is dissolved in a mixture of at least 50% by volume tertiary-butanol in water, the mixture is lyophilized, the resulting lyophilized product is packaged in one vial with a sufficient amount of solvent comprising anhydrous ethanol and a suitable nonionic surfactant in a second vial. All steps are carried out with protection from light. In use, the contents of the second or diluent vial are added to the lyophilized product and mixed to constitute the epothilone analog and the resulting solution is diluted with a suitable diluent to produce a solution for intravenous injection containing the epothilone analog in a concentration of from about 0.1 mg/mL to about 0.9 mg/mL. A preferred surfactant is polyethoxylated castor oil and a preferred diluent is Lactated Ringer's Injection.Type: ApplicationFiled: November 4, 2008Publication date: March 12, 2009Inventors: Rebanta Bandyopadhyay, Timothy M. Malloy, Andrea Panaggio, Krishnaswamy Srinivas Raghavan, Sailesh Amilal Varia
-
Patent number: 7022330Abstract: A process for formulating certain epothilone analogs for parenteral administration is disclosed wherein the analog is dissolved in a mixture of at least 50% by volume tertiary-butanol in water, the mixture is lyophilized, the resulting lyophilized product is packaged in one vial with a sufficient amount of solvent comprising anhydrous ethanol and a suitable nonionic surfactant in a second vial. All steps are carried out with protection from light. In use, the contents of the second or diluent vial are added to the lyophilized product and mixed to constitute the epothilone analog and the resulting solution is diluted with a suitable diluent to produce a solution for intravenous injection containing the epothilone analog in a concentration of from about 0.1 mg/mL to about 0.9 mg/mL. A preferred surfactant is polyethoxylated castor oil and a preferred diluent is Lactated Ringer's Injection.Type: GrantFiled: January 17, 2002Date of Patent: April 4, 2006Assignee: Bristol-Myers Squibb CompanyInventors: Rebanta Bandyopadhyay, Timothy M. Malloy, Andrea Panaggio, Krishnaswamy Srinivas Raghavan, Sailesh Amilal Varia
-
Publication number: 20040122081Abstract: The present invention relates to a novel intravenous formulation for a taxane chemotherapeutic agent. The agent is formulated as a two-container, i.e. vial system, with one container holding the therapeutic agent in a solvent with a buffer and the other container holding a co-solvent in a buffer. The contents of the two containers are mixed prior to administration.Type: ApplicationFiled: November 7, 2003Publication date: June 24, 2004Inventors: Uday Shankar Gogate, Robert Kevin Perrone, Krishnaswamy Srinivas Raghavan
-
Patent number: 6670384Abstract: A process for formulating certain epothilone analogs for parenteral administration is disclosed wherein the analog is dissolved in a mixture of at least 50% by volume tertiary-butanol in water, the mixture is lyophilized, the resulting lyophilized product is packaged in one vial with a sufficient amount of solvent comprising anhydrous ethanol and a suitable nonionic surfactant in a second vial. All steps are carried out with protection from light. In use, the contents of the second or diluent vial are added to the lyophilized product and mixed to constitute the epothilone analog and the resulting solution is diluted with a suitable diluent to produce a solution for intravenous injection containing the epothilone analog in a concentration of from about 0.1 mg/mL to about 0.9 mg/mL. A preferred surfactant is polyethoxylated castor oil and a preferred diluent is Lactated Ringer's Injection.Type: GrantFiled: January 23, 2002Date of Patent: December 30, 2003Assignee: Bristol-Myers Squibb CompanyInventors: Rebanta Bandyopadhyay, Timothy M. Malloy, Andrea Panaggio, Krishnaswamy Srinivas Raghavan, Sailesh Amilal Varia
-
Publication number: 20030220391Abstract: Disclosed are pharmaceutical compositions which comprise an orally-active taxane derivative and a pharmaceutically acceptable solubilizing agent, and which provide effective and consistent oral absorption of the taxane derivative.Type: ApplicationFiled: December 19, 2002Publication date: November 27, 2003Inventors: Joseph Ballard Bogardus, Robert Kevin Perrone, Krishnaswamy Srinivas Raghavan, Sailesh Amilal Varia
-
Patent number: 6576651Abstract: The invention relates to methods of increasing the bioavailability of orally administered epothilones. Epothilones administered by the methods of the invention are sufficiently bioavailable to have a pharmacological effect The invention further relates to pharmaceutical compositions, pharmaceutical dosage forms, and kits for use in the methods of the invention.Type: GrantFiled: January 25, 2002Date of Patent: June 10, 2003Assignee: Bristol-Myers Squibb CompanyInventors: Rebanta Bandyopadhyay, Timothy M. Malloy, Andrea Panaggio, Krishnaswamy Srinivas Raghavan, Sailesh Amilal Varia
-
Publication number: 20020177615Abstract: The invention relates to methods of increasing the bioavailability of orally administered epothilones. Epothilones administered by the methods of the invention are sufficiently bioavailable to have a pharmacological effect. The invention further relates to pharmaceutical compositions, pharmaceutical dosage forms, and kits for use in the methods of the invention.Type: ApplicationFiled: January 25, 2002Publication date: November 28, 2002Inventors: Rebanta Bandyopadhyay, Timothy M. Malloy, Andrea Panaggio, Krishnaswamy Srinivas Raghavan, Sailesh Amilal Varia
-
Publication number: 20020169190Abstract: A process for formulating certain epothilone analogs for parenteral administration is disclosed wherein the analog is dissolved in a mixture of at least 50% by volume tertiary-butanol in water, the mixture is lyophilized, the resulting lyophilized product is packaged in one vial with a sufficient amount of solvent comprising anhydrous ethanol and a suitable nonionic surfactant in a second vial. All steps are carried out with protection from light. In use, the contents of the second or diluent vial are added to the lyophilized product and mixed to constitute the epothilone analog and the resulting solution is diluted with a suitable diluent to produce a solution for intravenous injection containing the epothilone analog in a concentration of from about 0.1 mg/mL to about 0.9 mg/mL. A preferred surfactant is polyethoxylated castor oil and a preferred diluent is Lactated Ringer's Injection.Type: ApplicationFiled: January 23, 2002Publication date: November 14, 2002Inventors: Rebanta Bandyopadhyay, Timothy M. Malloy, Andrea Panaggio, Krishnaswamy Srinivas Raghavan, Sailesh Amilal Varia
-
Publication number: 20020143038Abstract: A process for formulating certain epothilone analogs for parenteral administration is disclosed wherein the analog is dissolved in a mixture of at least 50% by volume tertiary-butanol in water, the mixture is lyophilized, the resulting lyophilized product is packaged in one vial with a sufficient amount of solvent comprising anhydrous ethanol and a suitable nonionic surfactant in a second vial. All steps are carried out with protection from light. In use, the contents of the second or diluent vial are added to the lyophilized product and mixed to constitute the epothilone analog and the resulting solution is diluted with a suitable diluent to produce a solution for intravenous injection containing the epothilone analog in a concentration of from about 0.1 mg/mL to about 0.9 mg/mL. A preferred surfactant is polyethoxylated castor oil and a preferred diluent is Lactated Ringer's Injection.Type: ApplicationFiled: January 17, 2002Publication date: October 3, 2002Inventors: Rebanta Bandyopadhyay, Timothy M. Malloy, Andrea Panaggio, Krishnaswamy Srinivas Raghavan, Sailesh Amilal Varia
-
Patent number: RE40387Abstract: The invention relates to methods of increasing the bioavailability of orally administered epothilones. Epothilones administered by the methods of the invention are sufficiently bioavailable to have a pharmacological effect. The invention further relates to pharmaceutical compositions, pharmaceutical dosage forms, and kits for use in the methods of the invention.Type: GrantFiled: June 9, 2005Date of Patent: June 17, 2008Assignee: Bristol-Myers Squibb CompanyInventors: Rebanta Bandyopadhyay, Timothy M. Malloy, Andrea Panaggio, Krishnaswamy Srinivas Raghavan, Sailesh Amilal Varia, Marvin Barry Cohen